Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 133 entries
View as:

Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04859751 Org: User:
Start: 03/23/21 End: 12/31/23 Due: 12/31/24

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05446883 Org: User:
Start: 09/23/22 End: 07/01/25 Due: 07/01/26

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06041035 Org: User:
Start: 10/31/23 End: 10/31/25 Due: 10/31/26

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06954246 Org: User:
Start: 06/04/25 End: 04/30/28 Due: 04/30/29

Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

Phase: N/A Priority: Normal
NCT ID: NCT04128163 Org: User:
Start: 06/05/19 End: 12/01/21 Due: 12/01/22

A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children

Phase: N/A Priority: Normal
NCT ID: NCT06151587 Org: User:
Start: 08/20/23 End: 06/30/27 Due: 06/30/28

CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05052567 Org: User:
Start: 10/21/21 End: 06/29/24 Due: 06/29/25

A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05758519 Org: User:
Start: 03/07/23 End: 06/30/23 Due: 06/30/24

A Study of QLS31905 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05278832 Org: User:
Start: 10/25/21 End: 12/31/23 Due: 12/31/24

A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05829616 Org: User:
Start: 04/17/23 End: 05/30/25 Due: 05/30/26

To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture

Phase: N/A Priority: Normal
NCT ID: NCT06898060 Org: User:
Start: 06/30/25 End: 05/31/27 Due: 05/31/28

Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study

Phase: N/A Priority: Normal
NCT ID: NCT06742216 Org: User:
Start: 11/03/20 End: 08/30/23 Due: 08/30/24

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Phase: N/A Priority: Normal
NCT ID: NCT04629846 Org: User:
Start: 11/23/20 End: 10/24/23 Due: 10/24/24

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03195569 Org: User:
Start: 03/01/17 End: 12/10/18 Due: 12/10/19

A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT07001839 Org: User:
Start: 06/30/25 End: 12/31/26 Due: 12/31/27

A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05603039 Org: User:
Start: 07/01/21 End: 12/30/23 Due: 12/30/24

A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04954456 Org: User:
Start: 06/02/21 End: 12/30/22 Due: 12/30/23

To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06742138 Org: User:
Start: 01/31/25 End: 12/31/28 Due: 12/31/29

QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

Phase: N/A Priority: Normal
NCT ID: NCT04233151 Org: User:
Start: 01/20/20 End: 07/30/25 Due: 07/30/26

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07025239 Org: User:
Start: 07/31/25 End: 07/31/29 Due: 07/31/30

A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05458076 Org: User:
Start: 07/03/22 End: 09/06/22 Due: 09/06/23

A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05920876 Org: User:
Start: 06/30/23 End: 08/31/25 Due: 08/31/26

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06383767 Org: User:
Start: 07/11/24 End: 07/31/28 Due: 07/31/29

A Study of Olanzapine in Patients With Acute Agitation

Phase: N/A Priority: Normal
NCT ID: NCT05803642 Org: User:
Start: 03/28/23 End: 07/02/24 Due: 07/02/25

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04550949 Org: User:
Start: 04/26/19 End: 06/10/22 Due: 06/10/23